Acetylcholinesterase inhibitor treatment is associated with relatively slow cognitive decline in patients with Alzheimer's disease and AD + DLB

J Alzheimers Dis. 2009;16(1):29-34. doi: 10.3233/JAD-2009-0926.

Abstract

Dementia can be caused by different diseases including Alzheimer's disease (AD), dementia with Lewy bodies (DLB), or both (AD + DLB). University of Kentucky AD Center pathologically-diagnosed AD and AD + DLB cases were evaluated who had three or more longitudinal antemortem mental status examinations (n = 156). Patients with important concomitant pathology (n = 5) or patients that were profoundly demented at recruitment (intake MMSE < 20; n = 86) were excluded to strengthen our ability to test the association of specific clinical and pathological indices. Patients with pathologically-diagnosed AD + DLB (n = 25) lost cognitive capacity faster than patients with AD alone (n = 40). In both diseases, treatment with acetylcholinesterase inhibitors was associated with a slower rate of cognitive decline.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / psychology*
  • Cholinesterase Inhibitors / therapeutic use*
  • Cognition / drug effects*
  • Cognition Disorders / drug therapy*
  • Cognition Disorders / psychology*
  • Databases, Factual
  • Disease Progression
  • Female
  • Humans
  • Logistic Models
  • Longitudinal Studies
  • Male
  • Models, Statistical
  • Neuropsychological Tests

Substances

  • Cholinesterase Inhibitors